P54: Phase IIa

PYM's 225-patient study did not show a statistical difference between treatment and placebo groups. Patients receiving P54 had a 17 percent reduction in the WOMAC pain index over two months compared to a 20 percent reduction for patients given placebo. Overall patient opinions showed that 47 percent of the treatment group and 40 percent of the placebo group had improvement or marked improvement. The treatment group experienced mild digestive upset. ...